Susquehanna International Group, LLP Chimerix Inc Call Options Transaction History

Susquehanna International Group, LLP

7 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	SELL	$1.67 - $2.35 $72,478 - $101,990	-43,400 Reduced 60.7%	28,100 $52,000
Q3 2022 Nov 14, 2022	BUY	$1.81 - $2.76 $129,415 - $197,339	71,500 New	71,500 $138,000
Q1 2022 May 16, 2022	SELL	$4.58 - $6.8 $676,466 - $1 Million	-147,700 Reduced 78.15%	41,300 $189,000
Q4 2021 Feb 14, 2022	BUY	$5.23 - $7.18 $681,469 - $935,554	130,300 Added 221.98%	189,000 $1.22 Million
Q3 2021 Nov 15, 2021	SELL	$5.94 - $8.75 $12,474 - $18,375	-2,100 Reduced 3.45%	58,700 $363,000
Q1 2021 May 17, 2021	SELL	$4.76 - $11.25 $612,136 - $1.45 Million	-128,600 Reduced 67.9%	60,800 $586,000
Q3 2017 Nov 14, 2017	BUY	$4.35 - $5.25 $823,889 - $994,350	189,400	189,400 $994,000

36.8M

72.2K

169K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $85M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.